ESMO TAT 2024

ESMO TAT 2024

ESMO TAT 2024

Advertisement

Anticancer Drug Sensitivity in ALK-Rearrangement-Positive NSCLC Using the CODRP Index-Based Test

Mary GreccoESMO TAT 2024 | April 30, 2024

Cancer organoid-based drug sensitivity tests have recently been investigated to predict responses to anticancer drugs.

Role of MicroRNAs on Anti-Apoptotic MCL-1/cIAP-2 Gene Expression in Patients With EGFR-Mutated NSCLC

Mary GreccoESMO TAT 2024 | April 30, 2024

A study that assessed the impact of miR-29a and miR-143 on gene expression in lung cancer.

Finding Missed Lung, Ovarian Cancer Patients With the Combination of AI and Clinical Knowledge

Mary GreccoESMO TAT 2024 | April 25, 2024

A study examined whether AI and clinical knowledge can identify more patients with lung and ovarian cancers.

Identifying Signature Biomarkers of Lung Adenocarcinoma Using Integrative Epigenomics, Transcriptomics Analysis

Mary GreccoESMO TAT 2024 | April 25, 2024

A study detailed the landscape of lung adenocarcinoma progression.

Selective KRAS G12C Inhibitor MK-1084 as Monotherapy, in Combination With Pembrolizumab: A Phase 1 Dose-Escalation Study

Mary GreccoESMO TAT 2024 | April 25, 2024

MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.

Advertisement

Advertisement

Advertisement

Latest News

KEYNOTE-799 Final Analysis Shows Regimen Has ‘Sustainable Efficacy’ in NSCLC

April 3, 2025

Subcutaneous Pembrolizumab Shows Non-inferiority to IV Pembrolizumab for Metastatic NSCLC

April 1, 2025

PACIFIC-R Final Analyses: Data Support ‘Long-Term Benefit’ of Durvalumab After CRT in Unresectable NSCLC

March 31, 2025

LAURA Updated OS Data Support ‘New Standard of Care’ for Unresectable Stage III EGFR-Mutated NSCLC

March 28, 2025

KRYSTAL Data on Adagrasib Plus Pembrolizumab in KRAS-Mutated NSCLC Presented at ELCC 2025

March 28, 2025

Dr. Girard Shares Insights From the COCOON Trial

March 27, 2025